Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 3—March 2013

Clinical and Therapeutic Features of Pulmonary Nontuberculous Mycobacterial Disease, Rio de Janeiro, Brazil

Karla Gripp Couto de Mello, Fernanda C.Q. Mello, Liamar Borga, Valeria Rolla, Rafael S. Duarte, Elizabeth P. Sampaio, Steven M. Holland, D. Rebecca Prevots, and Margareth P. DalcolmoComments to Author 
Author affiliations: Author affiliations: National School of Public Heath, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil (K.G.C. de Mello, L. Borga, M.P. Dalcolmo); School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro (F.Q. Mello); Oswaldo Cruz Institute, Rio de Janeiro (V. Rolla, E.P. Sampaio); Federal University of Rio de Janeiro (R.S. Duarte); and National Institutes of Health, Bethesda, Maryland, USA (S.M. Holland, D.R. Prevots)

Main Article

Table 6

Treatment regimens for all patients with ATS-defined PNTM, per infecting species, Brazil, 1993–2011*

Species Treatment regimen (%)†
Mycobacterium avium complex Clarithromycin, amikacin,ethambutol, rifampin (54.7)
Clarithromycin, ethambutol,quinolone, terizidon (28.3)

Clarithromycin, amikacin, ethambutol, quinolone‡ (17.0)
Mycobacterium kansasii Rifampin, ethambutol, isoniazid (52.5)

Rifampin, ethambutol, isoniazid, clarithromycin, amikacin (47.5)
M. abscessus Clarithromycin, amikacin (68.4)
Clarihromycin, amikacin, doxycycline (10.5)

Clarithromycin, amikacin, terizidon (21)
M. massiliense Clarithromycin, amikacin (33.3)
Clarithromycin, amikacin, terizidon (33.3)

Clarithromycin, amikacin, imipenem, tigeciclin (33.3)
M. fortuitum Clarithromycin, amikacin, quinolone (64.2)
Clarithromycin, amikacin, terizidon (28.5)
Clarithromycin, amikacin, quinolone, doxycycline (7.3)

*ATS, AmericanThoracic Society; PNTM, pulmonary nontuberculous mycobacterial disease.
†Median duration of treatment, 19 mo.
‡Quinolones: levofloxacin, ciprofloxacin, moxifloxacin, ofloxacin.

Main Article

Page created: February 13, 2013
Page updated: February 22, 2013
Page reviewed: February 22, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.